EUVIMEDEUVIMED entdecken
Metaanalyse

Efficacy and Safety of Tyrosine Kinase Inhibitors in Patients with Metastatic Pheochromocytomas/Paragangliomas

Yue Zhou iD, Yunying Cui, Dingding Zhang iD, Anli Tong iD

The Journal of Clinical Endocrinology & Metabolism · 15.02.2023 · 108 (3) · 755-766

DOI: 10.1210/clinem/dgac657 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 16.11.2022. Verfasst von Yue Zhou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Key Laboratory of Endocrinology, National Health Commission of the People's Republic of China, Peking Union Medical Coll…. Hauptthemen laut MEDLINE: Antineoplastic Agents, Pheochromocytoma, Paraganglioma, Adrenal Gland Neoplasms. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Tyrosine kinase inhibitors (TKIs) can be used to treat locally unresectable or distantly metastatic pheochromocytomas/paragangliomas (PPGLs), such as sunitinib, according to the National Comprehensive Cancer Network guidelines in 2022. However, the precise effect of different TKIs in metastatic PPGLs is still unclear.

Objective

The aim of this meta-analysis is to assess the efficacy and safety of TKIs in metastatic PPGLs.

Methods

The PubMed, Cochrane Library, Scopus, Clinical Trial, and Embase databases were searched by synonyms of 48 TKIs and metastatic PPGLs from inception up to August 2022. Outcomes were tumor response or survival data and the incidence of adverse events (AEs) after treatment. The MIONRS scale and the JBI's tools for case series were used for interventional and observational studies to assess risk of bias, respectively. The combined effects with fixed- or random-effect models, the combined median with the weighted median of medians method and their 95% CIs were reported.

Results

A total of 7 studies with 160 patients were included. Tumor responses in metastatic PPGLs in 5 studies with available data showed the pooled proportion of partial response (PR), stable disease, and disease control rate (DCR) of, respectively, 0.320 (95% CI 0.155-0.486), 0.520 (95% CI 0.409-0.630), and 0.856 (95% CI 0.734-0.979). The combined median progressive-free survival in 6 studies was 8.9 months (95% CI 4.1-13.5) and the proportion of those who discontinued due to AEs in 5 studies was 0.143 (95% CI 0.077-0.209).

Conclusion

This meta-analysis suggests that patients with metastatic PPGLs can benefit from TKI therapy with PR and DCR up to more than 30% and 80%. However, because of restricted studies, larger clinical trials should be performed in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsPheochromocytomaParagangliomaAdrenal Gland NeoplasmsHumansTyrosine Kinase InhibitorsProtein Kinase Inhibitors

Stichwörter der Autor:innen

MPPGLTKImeta-analysismetastatic pheochromocytomas/paragangliomassystematic reviewtyrosine kinase inhibitors

Substanzen

Antineoplastic AgentsTyrosine Kinase InhibitorsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Endocrinology, Key Laboratory of Endocrinology, National Health Commission of the People's Republic of China, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Med…
  • Medical Research Center, State Key laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.

ORCID-Profile: Yue Zhou, Dingding Zhang, Anli Tong

Zitieren

APA

Zhou, Y., Cui, Y., Zhang, D., & Tong, A. (2023). Efficacy and Safety of Tyrosine Kinase Inhibitors in Patients with Metastatic Pheochromocytomas/Paragangliomas. The Journal of Clinical Endocrinology & Metabolism, 108(3), 755-766. https://doi.org/10.1210/clinem/dgac657

Vancouver

Zhou Y, Cui Y, Zhang D, Tong A. Efficacy and Safety of Tyrosine Kinase Inhibitors in Patients with Metastatic Pheochromocytomas/Paragangliomas. The Journal of Clinical Endocrinology & Metabolism. 2023;108(3):755-766. doi:10.1210/clinem/dgac657

BibTeX
@article{Zhou2023,
  author = {Zhou, Yue and Cui, Yunying and Zhang, Dingding and Tong, Anli},
  title = {Efficacy and Safety of Tyrosine Kinase Inhibitors in Patients with Metastatic Pheochromocytomas/Paragangliomas},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2023},
  volume = {108},
  number = {3},
  pages = {755--766},
  doi = {10.1210/clinem/dgac657}
}
Kostenlos starten →